In this issue of the Report, we have an exclusive interview with Alexandria (Sasha) Latypova, MBA, a former pharmaceutical executive, and independent analyst. Her prior reports on TrialSite News that deaths reported in VAERS after COVID-19 vaccination are not randomly distributed according to manufacturing lots as they are with influenza vaccines. Instead, they are aggregated in specific “hot lots.”